Market Research Report
Allergic Rhinitis: Epidemiology Forecast to 2028
|Published by||GlobalData||Product code||912105|
|Published||Content info||44 Pages
Delivery time: 1-2 business days
|Allergic Rhinitis: Epidemiology Forecast to 2028|
|Published: July 31, 2019||Content info: 44 Pages||
Allergic rhinitis (AR) is a chronic inflammatory condition of the nasal mucosa, caused by immunoglobulin E (IgE)-mediated early-phase and late-phase hypersensitivity responses (Scadding, 2015). AR symptoms include rhinorrhea, nasal obstruction and blockage, nasal itching, and repetitive sneezing (Scadding, 2015; National Health Services, 2019). It is being increasingly recognized that if AR is poorly managed, it can have a major impact on quality of life, emotional well-being, sleep, daily activities, and productivity. AR is also associated with considerable economic burden (Linneberg et al., 2016)..
GlobalData epidemiologists utilized county-specific studies published in peer-reviewed journals to build the forecast for the The report includes a 10-year epidemiological forecast for the diagnosed incident, 12-month diagnosed prevalent, and 12-month total prevalent cases of AR in the 7MM.
The following data describes epidemiology of AR. GlobalData epidemiologists forecast an increase in the diagnosed incident cases of AR in the 7MM from 5,621,030 cases in 2018 to 5,660,994 cases by 2028, at an AGR of 0.07% during the forecast period. The 12-month diagnosed prevalent cases of AR in the 7MM are expected to increase from 76,455,380 cases in 2018 to 77,778,250 cases by 2028, at an AGR of 0.17%. The 12-month total prevalent cases of AR are also expected to increase from 149,371,883 cases in 2018 to 151,702,573 cases by 2028, at an AGR of 0.16%. AR is more common in women than men and is more common in the younger age groups. These trends are reflected in GlobalData's forecast for the diagnosed incident cases, and prevalent cases for the 7MM.
The Allergic Rhinitis Epidemiology series will allow you to -